Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study assessing Zofin for heart failure with preserved ejection fraction

X
Trial Profile

A study assessing Zofin for heart failure with preserved ejection fraction

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zofin (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Sponsors ZEO ScientifiX
  • Most Recent Events

    • 04 Mar 2024 According to a ZEO ScientifiX, Inc media release, company name changed from Organicell to ZEO ScientifiX.
    • 27 Oct 2020 New trial record
    • 20 Oct 2020 According to an Organicell media release, the company plans to collaborate with Regenerative Care Network (RCN) . This collaboration will focus on the conduct of clinical trials to take place at various medical institutions in Dallas and Houston, as soon as possible after an Investigational New Drug Application (IND) is filed with and approved by the FDA and Institutional Review Board (IRB) approval is received. Dr. Friedewald is expected to be the principal investigator for this study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top